Moreover, AKR1B10 overexpression was significantly contributed to poor OS in HCC patients with stage II-III (HR = 1.83, log rank P = 0.013, Figure 5E) and stage III-IV (HR = 1.98, log rank P = 0.021, Figure 5F). Here, AKR1B10 is linked to hepatocellular carcinoma.